Gilman Hill Asset Management Trimmed By $309,600 Its Amgen (AMGN) Position; Arrowhead Pharmaceuticals (ARWR) Had 1 Bullish Analysts

October 11, 2017 - By Dolores Ford

Among 6 analysts covering Arrowhead Research Corp (NASDAQ:ARWR), 1 have Buy rating, 0 Sell and 5 Hold. Therefore 17% are positive. Arrowhead Research Corp had 16 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Wednesday, November 30 by PiperJaffray. The firm has “Hold” rating by RBC Capital Markets given on Wednesday, August 5. The company was downgraded on Wednesday, November 30 by Cantor Fitzgerald. The firm has “Buy” rating by Cantor Fitzgerald given on Friday, August 19. The firm has “Buy” rating given on Thursday, November 10 by Chardan Capital Markets. As per Thursday, September 14, the company rating was maintained by Piper Jaffray. The rating was maintained by Jefferies with “Hold” on Thursday, August 3. The firm has “Mkt Perform” rating given on Wednesday, November 30 by William Blair. Cantor Fitzgerald maintained Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) on Monday, September 25 with “Hold” rating. Piper Jaffray downgraded the shares of ARWR in report on Wednesday, November 30 to “Neutral” rating. See Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) latest ratings:

25/09/2017 Broker: Cantor Fitzgerald Rating: Hold New Target: $2.0 Maintain
18/09/2017 Broker: William Blair Old Rating: Market Perform New Rating: Outperform Upgrade
14/09/2017 Broker: Piper Jaffray Rating: Hold New Target: $3.0 Maintain
15/09/2017 Broker: Cantor Fitzgerald Rating: Hold New Target: $2.0
03/08/2017 Broker: Jefferies Rating: Hold New Target: $2.0000 Maintain
26/06/2017 Broker: Jefferies Rating: Hold New Target: $2.0000 Maintain

Gilman Hill Asset Management Llc decreased Amgen Inc (AMGN) stake by 31.51% reported in 2017Q2 SEC filing. Gilman Hill Asset Management Llc sold 1,800 shares as Amgen Inc (AMGN)’s stock declined 9.68%. The Gilman Hill Asset Management Llc holds 3,912 shares with $674,000 value, down from 5,712 last quarter. Amgen Inc now has $134.37 billion valuation. The stock decreased 0.88% or $1.64 during the last trading session, reaching $184.15. About 3.23 million shares traded or 23.75% up from the average. Amgen, Inc. (NASDAQ:AMGN) has risen 5.27% since October 11, 2016 and is uptrending. It has underperformed by 11.43% the S&P500.

The stock increased 2.76% or $0.11 during the last trading session, reaching $4.1. About 1.03 million shares traded. Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) has declined 67.27% since October 11, 2016 and is downtrending. It has underperformed by 83.97% the S&P500.

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. The company has market cap of $306.57 million. Using a portfolio of ribonucleic acid chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes. It currently has negative earnings. The Firm is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins.

Among 22 analysts covering Amgen Inc. (NASDAQ:AMGN), 11 have Buy rating, 0 Sell and 11 Hold. Therefore 50% are positive. Amgen Inc. had 64 analyst reports since August 3, 2015 according to SRatingsIntel. Raymond James initiated the shares of AMGN in report on Tuesday, September 1 with “Market Perform” rating. The stock of Amgen, Inc. (NASDAQ:AMGN) earned “Hold” rating by Bernstein on Wednesday, June 7. The rating was maintained by Jefferies on Sunday, August 27 with “Buy”. As per Wednesday, July 12, the company rating was maintained by Oppenheimer. The firm earned “Buy” rating on Thursday, July 27 by Argus Research. On Tuesday, December 13 the stock rating was initiated by Oppenheimer with “Outperform”. The firm earned “Buy” rating on Friday, August 21 by Vetr. The rating was maintained by Oppenheimer on Friday, July 28 with “Buy”. On Tuesday, December 20 the stock rating was downgraded by Credit Suisse to “Neutral”. The rating was maintained by Mizuho on Friday, July 14 with “Buy”.

Since May 24, 2017, it had 0 insider purchases, and 2 sales for $1.02 million activity. BALTIMORE DAVID sold $569,541 worth of stock or 3,700 shares. Patton Cynthia M also sold $451,164 worth of Amgen, Inc. (NASDAQ:AMGN) on Wednesday, May 24.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Dolores Ford




Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: